Misfolding, oligomerization, and aggregation of the amyloid-β (Aβ) peptide is widely recognized as a central event in the pathogenesis of Alzheimer's disease (AD). Recent studies have identified soluble Aβ oligomers as the main pathogenic agents and provided evidence that such oligomeric Aβ aggregates are neurotoxic, disrupt synaptic plasticity, and inhibit long-term potentiation. A promising therapeutic strategy in the battle against AD is the application of short synthetic peptides which are designed to bind to specific Aβ-regions thereby neutralizing or interfering with the devastating properties of oligomeric Aβ species. In the present study, we investigated the neuroprotective properties of the amyloid sequence derived pentapeptide LPYFDa in vitro as well as its memory preserving capacity against Aβ42-induced learning deficits in vivo. In vitro we showed that neurons in culture treated with LPYFDa are protected against Aβ42-induced cell death. Moreover, in vivo LPYFDa prevented memory impairment tested in a contextual fear conditioning paradigm in mice after bilateral intrahippocampal Aβ42 injections. We thus showed for the first time that an anti-amyloid peptide like LPYFDa can preserve memory by reverting Aβ42 oligomer-induced learning deficits.
INTRODUCTION
Progressive neurodegeneration and cognitive decline are typical features of Alzheimer's disease (AD), the most common form of dementia [1] . Besides the formation of neurofibrillary tangles, it is widely acknowledged that the aggregation of amyloid-β (Aβ) initiates a complex series of events that ultimately results in neuronal cell death particularly in forebrain regions, which is paralleled by the cognitive and behavioral de-cline that is characteristic for pathogenesis of AD. Aβ is generated by sequential proteolytic cleavage from the amyloid-β protein precursor (AβPP) by βand γsecretases (amyloidogenic processing). Alternatively AβPP can be cleaved by α-secretase within the Aβ sequence which prevents the generation of Aβ peptide. Once released, Aβ due to its physico-chemical properties has the strong tendency to misfold, oligomerize and to aggregate into fibrils and plaques [2] .
Although amyloid plaques represent a major hallmark of AD, they correlate poorly with the progression of the disease [3] . Interestingly, more recent studies have identified soluble Aβ-oligomer assemblies as the main pathogenic agents which, in contrast to plaques, do correlate well with the mental decline ob-served in AD patients [1, [4] [5] [6] [7] . Furthermore, soluble Aβ oligomers have been shown to be neuro-and synaptotoxic and to inhibit long-term potentiation (LTP) [8] [9] [10] [11] [12] . Acute application of oligomeric Aβ leads to internalization of glutamatergic AMPA and NMDA receptors and finally to synaptic downscaling [13, 14] . However, it should be appreciated that next to its pathological properties, Aβ, notably in very low physiological concentrations, may have an important role in synaptic plasticity and normal brain functioning [10, 15, 16] . The endogenous level of Aβ in the brain is regulated by synaptic activity in vivo, suggesting a dynamic feedback loop involving AβPP metabolism and Aβ that may modulate synaptic activity [1] . Recently, Garcia-Osta and coworkers showed that depletion of endogenous Aβ by a single intrahippocampal (i.h.) administration of anti-Aβ-antibody leads to disrupted memory retention in rats [17] . During the pathogenesis of AD, the equilibrium of Aβ generation and Aβ clearance is disturbed, which eventually leads to elevated Aβ levels, increased Aβ aggregation, and impaired memory function [10] .
Multiple therapeutic strategies have been developed since the second half of the previous century [18] . Unfortunately, most of the currently available therapies target only the symptoms, acting on presumed downstream neurotoxic pathogenic mechanisms without tackling the cause and thus hardly able to affect the progression of the disease. Experimental data from animal studies using immunotherapy in order to remove Aβ from the brain were highly promising [19] . However, clinical trials with active immunization against Aβ were halted due to severe brain inflammation and premature death of several patients [20, 21] .
Consequently, as a therapeutic strategy, compounds were developed that could inhibit or delay the development of Aβ aggregation, fibrillization, and/or plaque formation and were thus potentially capable of protecting neurons from Aβ toxicity. As part of this approach, small peptides derived from the Aβ sequence were designed, such as the pentapeptide LPYFDa, which seemed to offer a promising starting point to develop potential drugs that can somehow revert the devastating impact of Aβ aggregates. The advantage of such compounds, in comparison to other putative therapeutic approaches for AD such as vaccination, is that they specifically target the abnormal conformation of Aβ without interfering with any possible physiological function of the soluble, monomeric Aβ peptide.
There have been numerous attempts to develop treatments developed to interfere with various key steps in the amyloidogenic process. Promising putative treatments may be those designed to inhibit steps that precede Aβ peptide aggregation, by blocking production of the toxic soluble Aβ oligomers in the first place, or by reversing, somehow, the toxic effect of these oligomers.
In the present study we established an in vivo model in the mouse for Aβ-induced memory impairment through a single bilateral injection of oligomeric Aβ 42 into the hippocampus and explored in this model whether LPYFDa can be beneficial against the Aβinduced cognitive deficits. Furthermore, we investigated the neuroprotective properties of Aβ-derived synthetic β-sheet breaker peptide Leu-Pro-Tyr-Phe-Aspamide (LPYFDa) [22, 24] against the neurotoxic effects of soluble Aβ 42 oligomers in cultured mouse primary cortical neurons (PCN). Finally, we employed molecular modeling and docking experiments to reveal part of the putative mechanism of action of these peptides.
MATERIAL AND METHODS

Compounds
The β-sheet breaker LPYFDa was synthesized in our laboratories by a solid-phase procedure involving the use of Merrifield resin and Boc chemistry. Purity control and structure verification were carried out by amino acid analysis and mass spectrometry as previously described [25] . The control peptide (scrP), which is a scrambled version of the LPYFD peptide (Pro-Asp-Tyr-Leu-Phe-amide), and Aβ 1−42 (Aβ 42 ) were purchased from EZBiolab Inc. (Carmel, USA). Anti-Aβ antibody (6E10) was obtained from Covance (Emeryville, USA). Other compounds used in this study were purchased from Invitrogen (Carlsbad, USA) or Sigma-Aldrich Corporation (St. Louis, USA).
Preparation of Aβ-oligomers
Oligomeric Aβ 42 was prepared as described by Dahlgren and colleagues [26] . In short, the synthetic Aβ 42 peptide was initially dissolved in 1,1,1,3,3,3hexafluoro-2-propanol (HFIP) to a concentration of 1 mM. The peptide solution was divided into aliquots and the HFIP removed by evaporation under vacuum (SpeedVac; Savant Instruments, Hyderabad, India). The dry peptide films were stored at −20 • C until further processing. Before use, the dry film Aβ 42 was dissolved in anhydrous DMSO to 5 mM followed by bath sonication (Decon, Hove Sussex, UK) for 10 min, subsequently diluted in neurobasal medium to a final concentration of 100 µM (stock solution) and incubated at 4 • C for 24 h to enable Aβ 42 oligomerization. The aggregation state and the secondary structure of the oligomeric Aβ 42 preparation was examined by sodium dodecyl sulfate (SDS)-PAGE Western blotting and Circular Dichroism (CD) spectrometry ( Fig. 1) .
Gel electrophoresis and Western blot analysis
Gel electrophoresis and Western blot analysis were adopted from Stine et al. [27] . Briefly, unheated samples in SDS sample buffer were applied to 10-20% tris-tricine gradient gels (BioRad, Munich, Germany), electrophoresed using tricine running buffer, and subsequently transferred to 0.45-µm polyvinylidene difluoride membranes (Millipore, Bilerca, USA). Membranes were blocked with 1% I-Block (Tropix, Bedford, USA) in Trisbuffered saline containing 0.0625% Tween-20. Blots were incubated with primary antibody 6E10 overnight (1:2000; mouse monoclonal against Aβ residues 1-16; Covance Emeryville, USA). Immunoreactivity was detected using enhanced chemiluminescence (Pierce Biotechnology, Rockford, USA) and imaged on an Kodak X-Ray film (Eastman Kodak Company, Rochester, USA) ( Fig. 1A ). Molecular weight values were estimated using the PageRuler (Fermentas International, Ontario, Canada) pre-stained molecular weight marker.
CD spectrometry
CD measurements were performed at 25 • C on a CD Spectrometer Model 62DS (AVIV Associates Inc., Lakewood, USA) using a quartz cell of 0.1 cm pathlength. All spectra were averages of four scans; the resolution was 1 nm. The oligomerized Aβ was diluted in PBS to a concentration of 25 µM. The samples were sonicated for 10 min immediately after dissolution. CD spectra were expressed as mean residue ellipticity [Θ] MR in units of deg cm 2 dmol −1 (Fig. 1B) . The percentages of secondary structures were analyzed using the K2D2 program [28] .
Molecular modeling
Stochastic conformational search. EDMC calculations
The conformational space was explored using the method previously employed by Liwo et al. [29] , which includes the electrostatically driven Monte Car-lo (EDMC) method [30, 31] implemented in the ECEP-PAK [32] package. Conformational energy was evaluated using the ECEPP/3 force field [33] . Hydration energy was evaluated using a hydration-shell model with a solvent sphere radius of 1.4 Å and atomic hydration parameters that have been optimized using nonpeptide data (SRFOPT) [34, 35] . In order to explore the conformational space extensively, we carried out 10 different runs, each of them with a different random number. Therefore, we collected a total of 5000 accepted conformations. Each EDMC run was terminated after 500 energy-minimized conformations had been accepted. The parameters controlling the runs were the following: a temperature of 298.15 K was used for the simulations. A temperature jump of 1,000 K was used; the maximum number of allowed repetitions of the same minimum was 50. The maximum number of electrostatically predicted conformations per iteration was 400; the maximum number of random-generated conformations per iteration was 100; the fraction of random/electrostatically predicted conformations was 0.30. The maximum number of steps at one increased temperature was 20; and the maximum number of rejected conformations until a temperature jump is executed was 100. Only trans peptide bonds (ω ∼ = 180 • ) were considered. All accepted conformations were then clustered into families using the program ANA-LYZE [36, 37] by applying the minimal-tree clustering algorithm for separation, using all heavy atoms, energy threshold of 30 kcal.mol −1 , and RMSD of 0.75 Å as separation criteria. This clustering step allows a substantial reduction of the number of conformations and the elimination of repetitions. A more detailed description of the procedure used here is given in section 4.4 Computational Methods of reference [38] .
Docking studies
Two models for Aβ were used as target systems; the monomeric Aβ 42 elucidated by Crescenzi et al.
(monomeric model) [39] , PDB code 1IYT, and the pentameric aggregate Aβ 42 developed by Masman et al.
(pentameric model) [40] . The structures were prepared for docking study as follows: for the Aβ 42 molecules, water molecules were removed from the PDB file and hydrogen atoms were added; Gasteiger charges, atomic solvation parameters and fragmental volumes were merged to the target system. For both LPYFDa and scrP, the structure of the most populated family (results from the EDMC calculations) was taken as initial conformation. Gasteiger charges were assigned and . Bands correspond to monomeric up to tetrameric forms of Aβ 42 . B) CD spectrum of (×) Aβ 42 in PBS after 24 hours incubation at 4 • C. (-) fitted line data using K2D2 program. C)Schematic outline of the experimental procedure in vitro. PCN from C57BL6 mouse embryos (E14) were cultured for 6 days and then treated for 24 h with different concentrations of oligomerized Aβ 42 , β-sheet breaker peptides or combinations of both. On day 7 medium was completely exchanged and 24 h later the cell viability was assessed by an MTT reduction assay. D) Schematic outline of the experimental setup in vivo. C57BL/6J mice were cannulated 7 days prior i.h. injection with oligomerized Aβ 42 and/or β-sheet breaker peptides. One hour after the injection the animals were trained in a contextual fear conditioning paradigm. 24 hours after the training session memory performance was assessed. Cannula position was evaluated by methylene blue injection after the behavioural test. E) Representative coronal brain sections of a bilateral dorsal hippocampal (i.h.) injection with methylene blue counterstained with nuclear fast red. non-polar hydrogen atoms were merged. All torsions were allowed to rotate during docking. The docking energy grid was produced with the auxiliary program AutoGrid. The grid dimensions were 60 × 60 × 60 for the monomeric model, and 90 × 60 × 60 for the pentameric model, points along the x-, y-and z-axes, with points separated by 0.375 Å. The grids were chosen to be sufficiently large to cover significant portions of the putative binding sites. The center of the pentapeptide was positioned at the grid center. All graphic manipulations and visualizations were performed by means of the AutoDock Tools [41] and the Chimera [42] programs, and ligand docking with AUTODOCK 4 [43] . The Lamarckian genetic algorithm was utilized and the energy evaluations were set at 2.5 × 10 6 . A total of 250 accepted conformations were collected. Other parameters were set to default values.
Primary cortical neuron culture
PCN were prepared from embryonic brains (E14) of C57Bl/6J mice. The cortices were carefully dissected, meninges were removed, and the neurons separated by trituration. Cells were plated on poly-D-lysine precoated plates at a density of 1.2 × 10 5 cells/well (96 well plates). Neurobasal medium supplemented with 2% (v/v) B27-supplement, 0.5 mM glutamine and 1% (v/v) penicillin/ streptomycin was used as a culture medium. After 48 h, neurons were treated with 10 µM cytosine arabinoside for another 48 h to inhibit nonneuronal cell growth. Subsequently, the medium was completely exchanged, and, after 6 days of in vitro culture, the neurons were used for experiments.
Treatment of cells
Possible toxicity of LPYFDa, its control peptide scrP, and Aβ 42 oligomers was determined by incubating neuronal cultures for 24 h with different concentrations of the peptide solutions. The neuroprotective effect of LPYFDa was assessed by incubating neurons (cultured in 96 well plates) for 24 h with 20 µM oligomeric Aβ in the presence or absence of different concentrations of LPYFDa or control peptide. After the treatment, the medium was completely exchanged, and 24 h later, the cell viability was determined by an MTT-assay (Fig. 1C ). All treatments were performed in triplicates and the experiments were repeated at least two times.
Determination of cell viability by MTT-assay
Neuronal viability was determined by the colorimetric MTT [3-(4,5-dimethylthiazol-2-yl-)2,5-diphenylte trazolium bromide] assay as described previously [44] . 1.25 mg/ml MTT solution was added to each well of a 96 well plate. After 2 h of incubation, cells were lysed in acidic propan-2-ol solution (37% HCl/ propan-2-ol: 1/166). The absorbance of each well was measured with an automated ELISA plate reader (BioRad, Munich, Germany) at 595 nm with a reference filter at 630 nm.
Animals
Behavioral experiments were performed with 9-12 weeks old male C57Bl/6J mice (Harlan, Horst, The Netherlands). Individually housed mice were maintained on a 12 h light/dark cycle (lights on at 7.00 a.m.) with food (Hopefarms, standard rodent pellets) and water ad libitum. A layer of sawdust served as bedding. The animals were allowed to adapt to the housing conditions for 1-2 weeks before the experiments started. The procedures concerning animal care and treatment were in accordance with the regulations of the Ethical Committee for the use of experimental animals of the University of Groningen (DEC4668C).
Animal surgery
Double guide cannulae type C235 (Plastics One, Roanoke, USA) were implanted in the brain using a Kopf stereotactic instrument during Hypnorm/Midazolam (10 ml/kg, i.p.) anesthesia under aseptic conditions as previously described [45] with anteroposterior (AP) coordinates zeroed at Bregma directed toward both dorsal hippocampi (i.h.), AP -1.5 mm, lateral 1 mm, depth 2 mm [46] . Each double guide cannula with inserted dummy cannula and dust cap was fixed to the skull with dental cement (3M ESPE AG, Seefeld, Germany). Administration of 1 mg/ml finadyne (2.5 mg/kg s.c.) before the surgery served as analgesic. The animals were allowed to recover for 6-7 days before the behavioral measurements started.
Intrahippocampal injections
Bilateral i.h. injections were performed under short isofluran anesthesia using a Hamilton microsyringe fitted to a syringe pump unit (TSE systems, Bad Homburg, Germany) at a constant rate of 0.3 µl/min (final volume: 0.3 µl per side). The amount of injected Aβ 42 was of 15, 30, or 60 pmol and LPYFDa as well as the control peptide scrP in an amount of 150 pmol into the dorsal hippocampus. PBS (pH 7.5) served as vehicle. One hour after the injection the animals were subjected to a training session in a fear conditioning paradigm (Fig. 1D ). The number of animals per group varied from 5 to 9.
Fear conditioning
Fear conditioning was performed in a plexiglas cage (44 × 22 × 44 cm) with constant illumination (12 V, 10W halogen lamp, 100-500 lux). The training (conditioning) consisted of a single trial. Before each individual mouse entered the box, the box was cleaned with 70% ethanol. The mouse was exposed to the conditioning context for 180 s followed by a scrambled footshock (0.7 mA, 2 s, constant current) delivered through a stainless steel grid floor. The mouse was removed from the fear conditioning box 30 s after shock termination to avoid an aversive association with the handling procedure. Memory tests were performed 24 h after fear conditioning. Contextual memory was tested in the fear conditioning box for 180 s without footshock presentation. Freezing, defined as the lack of movement except for respiration and heart beat, was assessed as the behavioral parameter of the defensive reaction of mice by a time-sampling procedure every 10 s throughout memory tests. In addition, mean activity of the animal during the training and retention test was measured with the Ethovision system (Noldus, Wageningen, The Netherlands).
Histology
Immediately after the behavioral test, mice were injected i.h. with methylene blue solution during sodiumpentobarbital anesthesia (0.1 ml/ 10 g, i.p.). Brains were removed and serially sectioned at 50 µm. Sections were stained on glass for 5 min in 0.1% nuclear fast red solution. To identify the location of the injection, sections were analyzed using light microscopy. Only data from animals in which the proper intrahippocampal site of injection was confirmed, were evaluated (Fig. 1E ).
Statistical analysis
Behavioral data were analyzed by analysis of variance (ANOVA) followed by the Bonferroni post-hoc test to determine statistical significance. For statistical analysis of the MTT assays, an unpaired Student's t test with unequal variance was used. A p-value < 0.05 was considered to be statistically significant. Data are presented as mean value ± standard error of the mean (SEM).
RESULTS
Characterization of the oligomeric Aβ 42
The state of aggregation of the oligomeric Aβ 42 preparation was determined by Western blot analysis. The results confirmed that the Aβ 42 preparation consisted of a mixture of small molecular weight Aβ 42 oligomers from monomeric to tetrameric Aβ 42 (Fig. 1A) . In addition, we used CD spectrometry to characterize the secondary structure of Aβ 42 in solution. We could show that our oligomeric Aβ 42 preparation consists of 43.02% β-sheets, 5.40% α-helix, and 51.58% random-coil conformation (Fig. 1B) , which shows a good correlation to the conformation behavior of Aβ 42 aggregates observed by Masman et al. [40] .
Molecular modeling and stochastic conformational search. EDMC calculations
To have a better view at the molecular level, it is crucial to assess the conformational behavior of the pentapeptides in solution. Therefore, LPYFDa and scrP were selected for energy calculations to determine the biologically relevant conformations. The results of the theoretical calculations are summarized in Table 1 . Calculations yielded a large set of conformational families for each peptide studied. The total number of conformations generated was 62515 and 65056, for LPYF-Da and scrP respectively, whereof 5000 conformations for each pentapeptide were accepted. In the clustering procedure, an R.M.S.D (Root Mean Square Deviation) of 0.75 Å and a ∆E of 30 kcal mol −1 were used. The number of families after clustering was 220 and 323, for LPYFDa and scrP, respectively. The total number of families accepted with a relative population higher than 0.50% was 10 and 25, for LPYFDa and scrP, respedtively, that sum up to ca 90% of all conformations. All low-energy conformers of pentapeptides studied here were then compared to each other. The comparison involved the spatial arrangements, relative energy, and populations. The LPYFDa evaluation showed that the most populated family (50.04%) is also the energetically preferred one, while its second most populated family (15.36%) has a relative energy of 0.03 kcal mol −1 above the global minimum. This small energetic difference is due to a slight reorientation of the side-chain of the residue Phe (see Fig. 2A ), while the rest of the structure showed approximately the same orientation. On the other hand, the most populated family of scrP (22.92%) showed a relative energy of 1.18 kcal mol −1 above the global minimum and a relative population of 6.38%. It was observed that LPYFDa is confrontationally, generally more restricted than scrP, with a preference to form folded structures, while scrP tended to form semi-extended or fully-extended conformations. Spatial views of selected conformations, for LPYFDa and scrP are shown in Fig. 2 .
Docking studies
Monomeric model
Two potential binding sites were found by using a single blind docking run (results not shown) on the monomeric Aβ 42 molecule (PDB code 1IYT), which comprises two α-helix moieties (residues 8-25 and 29-39) connected by a loop (residues 26-28). Site I encompasses the residues 21-26 containing Glu 22 and Asp 23 , which were previously identified as residues for aggregation of the oligomers [40, 47] . Site II includes residues 6-12 located in the portion of the molecule that loses all structural organization after oligomer formation, thus forming the so-called disordered region. In Table 2 the two most populated families of the complexes of LPYFDa and scrP with the monomeric Aβ 42 are summarized. LPYFDa showed lower binding energies, while site II was in general energetically preferred over site I but families on site II poorly populated. In general it can be concluded that LPYFDa binds stronger to the monomeric Aβ 42 than scrP.
Pentameric model
As previously reported by Masman et al. [40] , the Aβ 42 aggregates contain two β-sheet moieties (β1, residues 18-26 and β2, residues 31-42) organized into a parallel interchain orientation, which were proposed as intermolecular binding sites for the pentameric conformation. Moreover, a third possible site for interactions with ligand molecules was postulated, which involves the β1 and β2 portions of the chain located at Table 2 The two most populated families of LPYFDa and scrP found by docking simulations on the monomeric and pentameric Aβ 42 peptide and the corresponding binding energies (E B ) of the complexes. The binding constant (K B ) and the relative populations (%P) are also shown the edge of the aggregate. This site is orientated into axis of the oligomers, in the same direction where the oligomers grows by aggregation. Table 2 shows the two most populated families of the complexes of LPYF-Da and ScrP with the pentameric Aβ 42 . For all the sites proposed, LPYFDa showed lower binding energies than scrP. Interestingly, both pentapeptide LPYF-Da and scrP, revealed an energetic preference for site β1. LPYFDa was designed on the basis of Soto's pentapeptide LPFFD, which derives from the amino acid sequence Leu 17 -Val-Phe-Phe-Ala 21 of Aβ 42 , being the β1 portion of the aggregate. Figure 3 shows the atomic details of the interactions of the best complex (family β1 1, in Table 2) of the second and third chain of the aggregate. Also, a second salt bridge links the Lys16 to the Asp residue of LPYFDa. All salt bridges, indicated with a blockarrow that points to the positive member of the interaction, revealed an interacting distance of approximately 3.5 Å. All the ligand-target contacts are depicted as wireframe spheres. An important hydrophobic pocket was formed between the residues Phe 20 and Val 18 of the aggregate, and the residues Leu, Pro and Phe of the pentapeptide LPYFDa. This hydrophobic pocket is indicated with a dashed line.
LPYFDa is neuroprotective against oligomeric Aβ 42 in vitro
Part of our study was to assess the neuroprotective potential of the β-sheet breaker LPYFDa against Aβ-induced toxicity. Therefore, we first determined the toxic effect of the Aβ 42 oligomer preparation in vitro on cultured PCN. Neuronal cultures were exposed to increasing concentrations of oligomerized Aβ 42 for 24 h, followed by an MTT-reduction assay to assess cell viability. The results showed a clear Aβ-induced, dose dependent decrease in cell survival reaching significance at concentrations higher than 10 µM (Fig. 4A ). For the subsequent experiments we used oligomeric Aβ 42 at a concentration of 25 µM as a toxic stimulus.
Second, we investigated if LPYFDa or the control peptide scrP exhibited any toxicity to PCN and whether the β-sheet breaker peptides were capable to overcome the toxic effect of oligomeric Aβ 42 . For this purpose PCN were exposed to different concentrations of LPYFDa or scrP alone, Aβ 42 alone (25 µM) or β-sheet breaker peptides and Aβ 42 together for 24 h. The results showed that LPYFDa and scrP alone were not A B toxic to PCN at any tested concentration (Fig. 4B ). Furthermore, the control peptide scrP was not able to protect the neurons from Aβ-induced toxicity (Fig. 4C) .
In contrast, we could demonstrate a dose dependent neuroprotective effect of LPYFDa against Aβ-induced toxicity, reaching significance at 4 µM LPYFDa and higher (Fig. 4D) .
A single intrahippocampal injection of oligomeric Aβ 42 induces cognitive deficits in contextual fear conditioning
One hour prior to the training session in a contextual fear conditioning paradigm C57BL/6J mice received a single injection of oligomeric Aβ 42 (15, 30, or 60 pmol) or vehicle. Injections did not affect locomotion or the shock reaction during training (data not shown). The vehicle injected animals displayed an average relative freezing behavior of 58.9 ± 2.9%, which did not differ from untreated control animals (61.1 ± 2.4%). The mice injected with Aβ 42 showed a dose dependent decrease in freezing behavior (Fig. 5A ). 15 pmol Aβ 42 caused an average relative freezing of 50.0 ± 4.2%, which was not significantly different from the vehicleinjected animals. However, the mice injected with 30 pmol and 60 pmol of Aβ 42 had significantly reduced freezing scores compared to the vehicle group (36.2 ± 4.6%; p = 0.024 and 33.3 ± 5.3%; p = 0.037).
Next, we investigated whether LPYFDa is able to revert the Aβ-induced memory deficits. Therefore, we injected mice with 150 pmol LPYFDa or 150 pmol of the non specific control peptide scrP in the presence or absence of 30 pmol oligomerized Aβ 42 into the hippocampus. The LPYFDa and the scrP injected mice showed an average freezing of 61.1 ± 5.0% and 63.0 ± 5.5% which did not significantly differ from the untreated (61.1 ± 2.4%) or vehicle injected group (58.9 ± 2.9%).
However, LPYFDa co-injected with Aβ 42 was able to abolish the Aβ 42 oligomer-induced memory impairment (57.4 ± 5.2% versus 36.2 ± 4.46%; p = 0.039). Co-injection of Aβ with the control peptide scrP, which resulted in an average freezing score of 48.0 ± 4.9%, did not significantly reverse the Aβ-induced memory deficits (Fig. 5B) .
These results indicate that LPYFDa can reverse the detrimental effects of Aβ 42 oligomers and subsequent impaired memory performance.
DISCUSSION
In the present study, we could show that Aβ 42 oligomers are toxic to primary cortical neurons in cul-ture in a dose-dependent manner (Fig. 4A) . These results are in line with studies by Dahlgren and colleagues, who reported that the oligomeric form of Aβ 42 is 10 fold more toxic when compared to the fibrillar form [26] . These and our present findings support the growing general view that, in particular, oligomeric Aβ 42 peptides contribute to the progressive neuronal loss and the associated memory impairment observed in AD patients. Indeed, several studies showed that elevated levels of soluble oligomeric Aβ correlate strongly with cognitive decline in AD patients [6, 7] . Walsh and colleagues observed that a low-n oligomeric assembly of naturally secreted human Aβ alters hippocampal synaptic plasticity by inhibiting LTP [48] . Also the number of dendritic spines was dramatically decreased when neurons were incubated with Aβ oligomers, but not with monomers [48] . However, the loss in spines could be reverted by treating neurons with an anti-Aβ antibody [14] .
A possibility to counteract the injurious effects of oligomeric Aβ is by modulating its aggregation. Crucial for the aggregation process of the Aβ molecule are the hydrophobic residues (amino acids 17-21: LVFFA) within the internal region of the Aβ peptide. Experiments by Hilbich and colleagues revealed that replacement of those hydrophobic residues by hydrophilic residues results in impaired fibril formation [49] . These and other findings eventually led to the concept of βsheet breakers as therapeutic strategy for AD as proposed by Soto et al. [50, 51] . The initially synthesized compounds were peptides of 11 to 5 amino acids targeting the center region of the Aβ peptide and evolved to compounds like LPFFD (iAβ5) and/or LPYFDa. These pentapeptides are partially homologous to this hydrophobic center region and bind with a relatively high affinity to Aβ [52] [53] [54] by similar intermolecular interactions, leading to a competitive replacement of Aβ molecules. A major drawback with peptide drugs for neurological disorders is their rapid degradation in vivo by proteolytic enzymes and their poor bloodbrain permeability [55] . These issues were overcome by chemical modifications, like C-terminal amidation and N-terminal carboxylation, which resulted in increased half life in vivo and rapid brain uptake [54] . Although our knowledge of the biochemistry in respect to catabolism and brain uptake of certain aggregation inhibitor peptides has developed greatly in recent years, the detailed mechanisms of action are still poorly understood. Therefore, it is essential to elucidate and study the three dimensional structure of the Aβ peptide/aggregation inhibiting peptide complex to gain more insight into the molecular dynamics of the Aβ aggregation process.
We used computational modeling and docking experiments to address this question. Interestingly our docking results showed that LPYFDa binds preferably to the β1 portion of the aggregate ( Table 2 and Fig. 3 ), which has a good correlation with the design of this pentapeptide, since LPYFDa derives from the wild-type sequence Leu 17 -Val-Phe-Phe-Ala 21 of Aβ 42 , which is contained in this portion of the aggregate. Our docking results did not show any binding preference of LPYFDa (nor scrP) for the monomeric or the pentameric Aβ.
In the present study, we showed that the pentapeptide LPYFDa can protect cultured neurons from oligomeric Aβ-induced cell death. Datki and colleagues reported similar results on neuronal-like cell lines, e.g., SHSY-5Y cells. They could show that a 5-fold molar excess of LPYFDa protects these cells from toxic effects of fibrillar Aβ [24, 56] . In our study we could confirm that a molar excess of LPYFDa can prevent Aβ 42 mediated neurotoxicity. Moreover, we demonstrated a dose-dependent protective effect of LPYFDa and that this pentapeptide already has significant neuroprotective properties even with a 6-fold molar excess of oligomeric Aβ 42 . Our results are also in agreement with other studies reporting protection by LPYF-Da against the rapid neuromodulatory action of fibrillar Aβ 42 demonstrated by in vitro and in vivo electrophysiology [23] .
We found that a single bilateral intrahippocampal injection of oligomeric Aβ 42 impairs memory formation if applied 1 h before the training session in a contextual fear conditioning paradigm. These findings are in line with several other studies, which consistently report on memory deficits after intracerebral injections of Aβ 42 peptides, although the experimental conditions vary in terms of the injected peptide, injection procedure, and behavioral tasks employed [57] [58] [59] [60] [61] [62] . It should be noted that these injections obviously lead to Aβ levels beyond the basal levels necessary for proper synaptic functioning. Garcia-Osta showed that neutralizing endogenous Aβ by an anti-Aβ antibody resulted in memory impairment which implies that physiological soluble Aβ levels are required for proper memory function [17] , which was recently confirmed by a study of Morley et al. [63] .
The peptide LPFFD, which was designed by the Soto group, was able to prevent fibrillogenesis in a rat brain model [64] and to reduce Aβ deposition a transgenic AD mouse model [54] . Most interestingly, iAβ5p was shown to reverse the memory impairment caused by intrahippocampal injections of Aβ fibrils in rats [65] . However, these studies did not reveal whether impairment of learning and memory after oligomeric Aβ injections could be counteracted by such compounds. A novelty of our study is that we used Aβ oligomers instead of the less effective Aβ fibrils. Therefore, an important aim of our study was to establish if a compound like LPYFDa is able to prevent Aβ oligomer-induced learning and memory deficits. We showed that a 5fold molar excess of LPYFDa to Aβ could overcome the detrimental effects of Aβ oligomers on memory. Thus, we provide evidence that so-called β-sheet breaker peptides such as LPYFDa bear therapeutic potential against Aβ-induced memory impairment. Moreover, it was recently demonstrated that intraperitoneally administered LPYFDa is able to cross the blood brain barrier and protects synapses against excitatory action of fibrillar Aβ [22] .
The mechanism of how these pentapeptides exert their protective effects on cell death and behavior is not yet fully understood. However, it should be noted that the two actions of Aβ reported here, namely, the neuronal degeneration following application of Aβ oligomers in vitro and memory loss following injections of Aβ oligomers in vivo may be unrelated. In hippocampal tissue extracted one hour after Aβ injection, we were unable to detect any caspase-3 cleavage which would indicate apoptotic cell death (data not shown). Furthermore, there are no studies so far that show toxic effects of oligomeric Aβ on neurons in vivo. Therefore, the effects on memory following an hour post-injection may not have a direct correlation with neuronal degeneration, but could simply reflect the effects of Aβ on synaptic integrity. It is well documented that the main effects of Aβ on synapses are inhibition of LTP [9, 66] and elimination of postsynaptic glutamate receptors [8, 67, 68] . Remarkably, the Aβ-induced synaptic dysfunction occurs rather rapidly, starting 20 minutes after application, and does not need chronic exposure [69] [70] [71] [72] . Furthermore, it is likely that the injected oligomeric Aβ does not remain unchanged in terms of its conformation, and the effects on memory may be due to changes of Aβ to other conformations. The importance of the Aβ conformation on memory was demonstrated by Lesne and collaborators [73] , who showed that only specific Aβ protein assemblies in the brain are able to impair memory [73] .
It remains elusive whether aggregation inhibiting peptides like LPYFDa directly bind to Aβ, and thereby prevent possible interactions between Aβ and neuronal membrane proteins, and in this way neutralize its toxic effect. We could consider two options of interaction with Aβ: 1) the pentapeptides bind to the monomeric Aβ, thus preventing and/or retarding the formation of toxic oligomers; and 2) the pentapeptides bind the Aβ oligomers already formed preventing and/or modulating, somehow, its neurotoxic properties. On the other hand, both above mentioned possibilities might act simultaneously comprising a third possible way of action of this peptide toward its neuroprotective effects.
Being aware of the many possible biological pathways that these peptides might follow while inducing neuroprotection, it is interesting to see whether these peptides show a preference to bind the monomeric Aβ or its soluble oligomers. Previous studies using CD spectrometry and molecular docking studies have been carried out on LPYFDa and other so-called β-sheet breaker peptides [24, 52, 74, 75] but none of them so far have demonstrated proof at the molecular level of the β-sheet breaking properties of these peptides. We also might consider the possibility that these peptides might act as "glue" that promote elongation to biologically inert larger aggregates, or conversely, bind to the monomeric Aβ and this way inhibits oligomer formation. By either of these actions, or both, the neurotoxicity of Aβ is decreased or reverted.
In summary, our findings provide evidence on how and where LPYFD interacts with Aβ mono-and oligomers, that LPYFDa neutralizes the neurotoxic activity of soluble Aβ oligomers, and in the present conditions can effectively prevent the oligomer-induced deficits in memory performance.
